Hemodynamic Effects of Sacubitril/Valsartan in Patients with Reduced Left Ventricular Ejection Fraction Over 24 Months: A Retrospective Study.
Mohammad AbumayyalehJonathan DemmerCarina KrackChristina PilsingerIbrahim El-BattrawyMichael BehnesAssem AweimerAndreas MüggeSiegfried LangIbrahim AkinPublished in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2022)
Follow-up 24 months after starting treatment with sacubitril/valsartan revealed sustained improvements in echocardiographic parameters, including LVEF, PAPsys, and cardiac valvular insufficiency. Rates of all-cause hospitalization and congestion had decreased significantly at follow-up. The mortality rate was higher in echocardiographic and functional nonresponders.
Keyphrases
- ejection fraction
- aortic stenosis
- left ventricular
- heart failure
- atrial fibrillation
- left atrial
- acute myocardial infarction
- mitral valve
- hypertrophic cardiomyopathy
- cardiovascular events
- cardiac resynchronization therapy
- risk factors
- single cell
- type diabetes
- aortic valve
- pulmonary hypertension
- cardiovascular disease
- transcatheter aortic valve replacement
- acute coronary syndrome